NTLA Intellia Therapeutics Inc.

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2023 financial results and operational highlights in a conference call on August 3, 2023, at 8 a.m. ET.

To join the call:

  • U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
  • Please visit this for a simultaneous live webcast of the call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at , beginning on August 3, 2023, at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at . Follow us on Twitter .

Intellia Contacts:

Investors:

Ian Karp

Senior Vice President, Investor Relations and Corporate Communications



Lina Li

Senior Director, Investor Relations and Corporate Communications





EN
27/07/2023

Underlying

NTLAIntellia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intellia Therapeutics Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.03
BKD Brookdale Senio...
XENE Xenon Pharmaceu... ... (+57)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

BKD BROOKDALE SENIOR LIVING INC.
XENE XENON PHARMACEUTICALS INC
SEDG SOLAREDGE TECHNOLOGIES INC.
RUN SUNRUN INC.
LTRX LANTRONIX INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LAKE LAKELAND INDUSTRIES INC.
CEVA CEVA INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ALB ALBEMARLE CORPORATION
EFR ENERGY FUELS
RELL RICHARDSON ELECTRONICS LTD.
NTLA INTELLIA THERAPEUTICS INC.
UAMY UNITED STATES ANTIMONY CORP.
BOMN BOSTON OMAHA
ICL ICL GROUP LTD.
LWLG LIGHTWAVE LOGIC
IMTX IMMATICS N V (A)
ARRY ARRAY TECHNOLOGIES
IMVT IMMUNOVANT
RLAY RELAY THERAPEUTICS
FLUX FLUX POWER HOLDINGS
GLUE MONTE ROSA THERAPEUTICS INC
ASTS AST SPACEMOBILE INC
TRDA ENTRADA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
APLD APPLIED BLOCKCHAIN INC
IE IVANHOE ELECTRIC INC
NUVL NUVALENT INC
COHR COHERENT CORP
CRML CLAL INDUSTRIES & BEVERAGES LTD
GPCR STRUCTURE THERAPEUTICS
OCS OCULIS HOLDING AG
LAES SEALSQ CORP
NB NIOCORP DEVELOPMENTS LTD.
METBV FORTREA HOLDINGS INC.
FTREV SAGIMET BIOSCIENCES INC
SGMT BYRNA TECHNOLOGIES INC
BYRN ENGENE HOLDINGS INC
ENGN SPYRE THERAPEUTICS INC.
SYRE NEUROGENE INC
NGNE RAMACO RESOURCES INC.
METC TOYO CO LTD
TOYO SERVE ROBOTICS INC
SERV UPSTREAM BIO INC
UPB CIDARA THERAPEUTICS INC.
CDTX AMERICAN BATTERY TECHNOLOGY COMPANY
ABAT TVARDI THERAPEUTICS INC
TVRD USA RARE EARTH INC
USAR HYCROFT MINING HOLDING CORPORATION
HYMC CATALYST PERINI STRATEGIC INCOM ORD
CSIOX CHARGEPOINT HOLDINGS INC.
CHPT KULR TECHNOLOGY GROUP INC.
KULR GRAFTECH INTERNATIONAL LTD.
EAF GLOBALSTAR INC.
GSAT INHIBRX BIOSCIENCES INC.
INBX KON TUM CONSTRUCTION MATERIALS ORD
10/10/25 October 10, 2025 1 EN
 PRESS RELEASE
Free
NTLA Intellia Therap...

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing R...

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 65,200 shares of Intellia’s common s...

October 3, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.03
ERICn Telefonaktiebol...
CE Celanese Corpor... ... (+28)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ERICn TELEFONAKTIEBOLAGET LM ERICSSON
CE CELANESE CORPORATION
ACHC ACADIA HEALTHCARE COMPANY INC.
BJRI BJ'S RESTAURANTS INC.
PTK POET TECHNOLOGIES
NTLA INTELLIA THERAPEUTICS INC.
CRSP CRISPR THERAPEUTICS AG
BH BIGLARI HOLDINGS B
STOK STOKE THERAPEUTICS
TWST TWIST BIOSCIENCE
BEAM BEAM THERAPEUTICS
PCVX VAXCYTE
LUMN LUMEN TECHNOLOGIES INC.
ENVX ENOVIX CORP
ASTS AST SPACEMOBILE INC
ZGN ERMENEGILDO ZEGNA NV
PRME PRIME MEDICINE INC
ENGN ENGENE HOLDINGS INC
RR RICHTECH ROBOTICS INC
NGNE NEUROGENE INC
CRML CRITICAL METALS CORP.
BKKT BAKKT HOLDINGS INC.
MNPR MONOPAR THERAPEUTICS INC.
KLRS KALARIS THERAPEUTICS INC
STEM STEM INC.
RKLB ROCKET LAB CORPORATION
BALY BALLY'S CORPORATION
ANGX ANGEL STUDIOS INC CL A
10/03/25 October 3, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
NTLA INTELLIA THERAPEUTICS INC.
09/25/25 September 25, 2025 1 EN
 PRESS RELEASE
Free
NTLA Intellia Therap...

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for ...

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinue to observe generally favorable safety data with no new drug-related events within the follow-up periodData presented today at the 5th International ATTR Amyloidosis Annual Meet...

September 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch